Abatacept for Post-Transplant Immune Suppression in Children and Adolescents Receiving Allogeneic Hematopoietic Stem Cell Transplants for Non-Malignant Diseases
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Abatacept (Primary) ; Ciclosporin; Mycophenolate mofetil
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Acronyms Aba NMD
- 10 Jun 2017 Biomarkers information updated
- 29 Feb 2016 Planned End Date changed from 1 Jan 2018 to 1 Jan 2020, according to ClinicalTrials.gov record.
- 29 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2018, according to ClinicalTrials.gov record.